Clinical studies have shown that Savolitinib, particularly in combination with other epidermal growth factor receptor (EGFR) inhibitors, can overcome resistance mechanisms in NSCLC that have failed previous treatments (6). This evidence concerns the gene EGFR and non-small cell lung carcinoma.